The benefit of antiinflammation treatment via IL-10 in diverse experimental models of heart failure


  • POPOVICI Mihail IMSP Institutul de cardiologie
  • MUNTEANU Mihaela IMSP Institutul de cardiologie
  • POPOVICI Ion IMSP Institutul de cardiologie
  • IVANOV Victoria IMSP Institutul de cardiologie
  • CIOBANU Lucia IMSP Institutul de cardiologie
  • MORARU Ion IMSP Institutul de cardiologie
  • ROTARU Victoria Universitatea de Stat de Medicină și Farmacie „Nicolae Testemițanu”
  • TACU Lilia Universitatea de Stat de Medicină și Farmacie „Nicolae Testemițanu”
  • TODIRAȘ Mihail Universitatea de Stat de Medicină și Farmacie „Nicolae Testemițanu”
  • COBEȚ Valeriu Universitatea de Stat de Medicină și Farmacie „Nicolae Testemițanu”



heart failure, IL-10, model of isolated heart perfusion, functional benefit


Aim. The in vitro estimation of IL-10 effects in diverse experimental models of heart failure (HF). Material and methods. HF was induced in rats either by Dx administration in cumulative dose of 16 mg/kg or by isoproterenol administration twice in dose of 150 mg/kg. IL-10 was i/p administration daily during 7 days after HF modeling in single dose of 50 mkg/kg. Functional effects were assayed using perfused isolated heart exposed to hemodynamic and neuroendocrine efforts. Results. IL-10 improved in a similar manner in both HF models capacity of the heart regarding its adaptation to effort by volume and resistance, the most important tool being increasing of isovolumic relaxation and contraction velocity by up to 19%. Noteworthy, IL-10 led to appearance of positive inotropic effect on ET-1 action associated with cardiac output enhancement. Likewise, IL-10 augmented myocardium tolerance to ischemia and reperfusion action according to significant lesser levels of the left ventricle end diastolic pressure. Finally, IL-10 increased coronary functional reserve inherent to acetylcholine action, and coronary flow raised by 25-33% during parasympathetic stimulation. Conclusion. IL-10 notably improves analogically the functional performances of the heart in various models of experimental heart failure during hemodynamic and neuroendocrine efforts, underlying that inflammation is an important pathogenic factor of HF regardless of myocardial injury kind.

Author Biographies

POPOVICI Mihail, IMSP Institutul de cardiologie

prof. univ., dr. hab. șt. med., academician al AȘM,

MUNTEANU Mihaela, IMSP Institutul de cardiologie


POPOVICI Ion, IMSP Institutul de cardiologie

dr. hab. șt. med., prof. cercetător

IVANOV Victoria, IMSP Institutul de cardiologie

dr. hab. șt. med., prof. cercetător

CIOBANU Lucia, IMSP Institutul de cardiologie

dr. hab. șt. med., conf. cercetător

MORARU Ion, IMSP Institutul de cardiologie

dr. șt. med., conf. cercetător

ROTARU Victoria, Universitatea de Stat de Medicină și Farmacie „Nicolae Testemițanu”

dr. șt. med., conf. univ.,

TACU Lilia, Universitatea de Stat de Medicină și Farmacie „Nicolae Testemițanu”

asistent univ.,

TODIRAȘ Mihail, Universitatea de Stat de Medicină și Farmacie „Nicolae Testemițanu”

dr. hab. șt. med., conf. univ.,

COBEȚ Valeriu, Universitatea de Stat de Medicină și Farmacie „Nicolae Testemițanu”

dr. hab. șt. med., prof. univ


Adamo L., Rocha-Resende C., Prabhu S. D., Mann

D. L. Reappraising the role of inflammation in heart failure. Nat. Rev. Cardiol., 2020; 17:269–285. doi:10.1038/s41569-019-0315-x. Bacmeister L., Schwarzl M., Warnke S., et al. Inflammation and fibrosis in murine models of heart failure. Basic Res. Cardiol.,2019; 114(3), 19. doi:10.1007/s00395-019-0722-5.

Anzai T. Inflammatory Mechanisms of Cardiovascular Remodeling. Circ J, 2018; 82(3):629-635. doi: 10.1253/circj.CJ-18-0063.

Thackeray JT., Hupe HC., Wang Y. et al. Myocardial Inflammation Predicts Remodeling and Neuroinflammation After Myocardial Infarction. Journal of Am. Coll. of Cardiology, 2018;17 71(3): 263-275.

Schirone L., Forte M., Palmerio S. et al. A Review of the Molecular Mechanisms Underlying the Development and Progression of Cardiac Remodeling. Oxidative Medicine and Cellular Longevity. 2017;

Glasenapp A., Derlin K., Wang Y. et al. Multimodality Imaging of Inflammation and Ventricular Remodeling in Pressure-Overload Heart Failure. Journal of Nuclear Medicine, 2020; 61(4):590-596. DOI:

Hedrich CM., Bream JH. Cell type-specific regulation of IL-10 expression in inflammation and disease. Immunol Res, 2010; 47(1-3):185-206. doi: 10.1007/s12026009-8150-5.

Minshawi F., Lanvermann S., McKenzie E. et al. The Generation of an Engineered Interleukin-10 Protein With Improved Stability and Biological Function. Front. Immunol. 2020; 11:1794. doi: 10.3389/fimmu.01794.

Dhingra S., Sharma A., Arora J. IL-10 attenuates TNFα-induced NF-B pathway activation and cardiomyocyte apoptosis. Cardiovasc. Res., 2009; 82(1), 59–66. doi:10.1093/cvr/cvp040.

Stafford N., Assrafally F., Prehar S. et al. Signaling via the Interleukin-10 Receptor Attenuates Cardiac Hypertrophy in Mice During Pressure Overload, but not Isoproterenol Infusion. Front. Pharmacol. 2020; 11:559220. doi: 10.3389/fphar..559220.

Saraiva M., Viera P., Garra A. Cytokines focus biology and therapeutic potential of IL-10. J.Exp. Med., 2019; 217(1) hptts://

McInnes I.B,. Illei G.G., Danning C.H. et al. IL-10 improves skin disease and modulates endothelial activation and leukocyte effector function in patients with psoriatic arthritis. J. Immunol., 2001; 167:4075–4082.

Schreiber S., Fedorak RN., Nielsen OH. et al. Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn disease. Gastroenterology, 2000; 119:1461-1472.

Langendorff O. Untersuchungen am unverlebenden augetierherzev. Pflugers Arch. 1985; vol. 61, p. 291-320.

Neely J., Rovetto M. Techniques for perfusing isolated rat heart. Methods Enzymol. 1975; vol. 39, p. 43-60.

Fioranelli M., Grazia RM. Twenty-five years of studies and trials for the therapeutic application of IL-10 immunomodulating properties. From high doses administration to low dose medicine new paradigm. J Integr Cardiol, 2014;1(1); 2-6. Doi: 10.15761/JIC.1000102

Иванов М. В., Попович М. И., Чебану Л. М., Иванов В. М., Попович И. М., Кобец В. А. Предикторная значимость маркеров воспаления в отношении паттерна постинфарктного ремоделирвоания миокарда. Кардиоваскулярная терапия и профилактика, 2018; 17(5), 17-24. SCOPUS IF 1.145.

Ivanov M., Tacu L., Todiraș M., Cobeț V. Atenuarea inflamației reduce cardiotoxicitatea doxorubicinii. Buletinul Academiei de Științe a Moldovei. Științe medicale. 2019; vol.1 (61), 208-212.

Cobet V., Ivanov, M., Tacu, L., et al. The TNF-alpha and ET-1 inhibition mitigates ischemia-reperfusion impact in diabetes induced heart failure. In: European Journal of Heart Failure. 2015; vol.17 (Suppl. S1), p.238 (IF 5,135).

Krishnamurthy P., Rajasingh J., Lambers E., Qin G., Losordo DW., Kishore R. IL-10 inhibits inflammation and attenuates left ventricular remodeling after myocardial infarction via activation of STAT3 and suppression of HuR. Circ Res. 2009; 104: e9–18.

Freund C., Schmidt-Ullrich R., Baurand A., Dunger S., Schneider W., Loser P., El-Jamali A., Dietz R., Scheidereit C., Bergmann MW. Requirement of nuclear factor-kappaB in angiotensin IIand isoproterenol-induced cardiac hypertrophy in vivo. Circulation. 2005; 111:2319–2325.

Verma SK., Krishnamurthy P., Barefield D et al. Interleukin-10 Treatment Attenuates Pressure Overload– Induced Hypertrophic Remodeling and Improves Heart Function via Signal Transducers and Activators of Transcription 3–Dependent Inhibition of Nuclear Factor-κB. Circulation, 2012;126:418-429.

Wang Y., Chen Q., Zhang Z. et al. Interleukin-10 overexpression improves the function of endothelial progenitor cells stimulated with TNF-α through the activation of the STAT3 signaling pathway. Int J Mol Med, 2014; 35(2):471-477.

Xu S., Zhang J., liu J et al. The role of interleukin-10 family members in cardiovascular diseases. Int Immunopharmacology, 2021; 94:107475.

Stumpf C., Seybold K., Petzi S. et al. Interleukin-10 improves left ventricular function in rats with heart failure subsequent to myocardial infarction. Eur J Heart Fail, 2008;10:733–739.